Advances in molecular biomarkers and liquid biopsy in gliomas

Dimitrios Mathios; Jillian Phallen

doi:10.1093/noajnl/vdac151

Advances in molecular biomarkers and liquid biopsy in gliomas

Dimitrios Mathios, Jillian Phallen

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

There have been significant strides toward understanding the molecular landscape of brain cancer. These advances have been focused on analyses of the tumor microenvironment and have recently expanded to include liquid biopsies to identify molecular biomarkers noninvasively. Moving from tissue to liquid-based analyses of molecular biomarkers has been challenging and currently, there are no approved noninvasive tests that are clinically useful. However, the emerging field of molecular liquid biopsy assay development in the neuro-oncology space has great potential to revolutionize the detection and monitoring of patients with brain cancer.

Original language	English (US)
Pages (from-to)	II15-II21
Journal	Neuro-Oncology Advances
Volume	4
DOIs	https://doi.org/10.1093/noajnl/vdac151
State	Published - Nov 1 2022

Keywords

circulating biomarker
circulating tumor DNA
glioblastoma
liquid biopsy

ASJC Scopus subject areas

Clinical Neurology
Oncology
Surgery

Access to Document

10.1093/noajnl/vdac151

Cite this

@article{6bae55d0903e489386b2477e22e19b3b,

title = "Advances in molecular biomarkers and liquid biopsy in gliomas",

abstract = "There have been significant strides toward understanding the molecular landscape of brain cancer. These advances have been focused on analyses of the tumor microenvironment and have recently expanded to include liquid biopsies to identify molecular biomarkers noninvasively. Moving from tissue to liquid-based analyses of molecular biomarkers has been challenging and currently, there are no approved noninvasive tests that are clinically useful. However, the emerging field of molecular liquid biopsy assay development in the neuro-oncology space has great potential to revolutionize the detection and monitoring of patients with brain cancer.",

keywords = "circulating biomarker, circulating tumor DNA, glioblastoma, liquid biopsy",

author = "Dimitrios Mathios and Jillian Phallen",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.",

year = "2022",

month = nov,

day = "1",

doi = "10.1093/noajnl/vdac151",

language = "English (US)",

volume = "4",

pages = "II15--II21",

journal = "Neuro-Oncology Advances",

issn = "2632-2498",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Advances in molecular biomarkers and liquid biopsy in gliomas

AU - Mathios, Dimitrios

AU - Phallen, Jillian

PY - 2022/11/1

Y1 - 2022/11/1

N2 - There have been significant strides toward understanding the molecular landscape of brain cancer. These advances have been focused on analyses of the tumor microenvironment and have recently expanded to include liquid biopsies to identify molecular biomarkers noninvasively. Moving from tissue to liquid-based analyses of molecular biomarkers has been challenging and currently, there are no approved noninvasive tests that are clinically useful. However, the emerging field of molecular liquid biopsy assay development in the neuro-oncology space has great potential to revolutionize the detection and monitoring of patients with brain cancer.

AB - There have been significant strides toward understanding the molecular landscape of brain cancer. These advances have been focused on analyses of the tumor microenvironment and have recently expanded to include liquid biopsies to identify molecular biomarkers noninvasively. Moving from tissue to liquid-based analyses of molecular biomarkers has been challenging and currently, there are no approved noninvasive tests that are clinically useful. However, the emerging field of molecular liquid biopsy assay development in the neuro-oncology space has great potential to revolutionize the detection and monitoring of patients with brain cancer.

KW - circulating biomarker

KW - circulating tumor DNA

KW - glioblastoma

KW - liquid biopsy

UR - http://www.scopus.com/inward/record.url?scp=85159235187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85159235187&partnerID=8YFLogxK

U2 - 10.1093/noajnl/vdac151

DO - 10.1093/noajnl/vdac151

M3 - Article

C2 - 36380861

AN - SCOPUS:85159235187

SN - 2632-2498

VL - 4

SP - II15-II21

JO - Neuro-Oncology Advances

JF - Neuro-Oncology Advances

ER -

Advances in molecular biomarkers and liquid biopsy in gliomas

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this